Chimerix (NASDAQ:CMRX) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Chimerix (NASDAQ:CMRX - Free Report) in a research report released on Tuesday,Benzinga reports. HC Wainwright currently has a $11.00 target price on the biopharmaceutical company's stock.

Separately, Wedbush reissued an "outperform" rating and issued a $6.00 target price on shares of Chimerix in a report on Tuesday, December 10th.

Chimerix Stock Performance

Chimerix stock traded down $0.01 during midday trading on Tuesday, reaching $5.16. The company's stock had a trading volume of 1,966,315 shares, compared to its average volume of 1,665,401. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $5.53. The stock's 50 day simple moving average is $3.72 and its 200 day simple moving average is $1.92. The firm has a market capitalization of $464.45 million, a PE ratio of -5.49 and a beta of 0.35.

Insider Buying and Selling at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares of the company's stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bender Robert & Associates acquired a new position in shares of Chimerix during the 4th quarter worth $37,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Chimerix during the 4th quarter worth $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix during the 4th quarter worth $62,000. Diadema Partners LP acquired a new position in shares of Chimerix during the 4th quarter worth $101,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Chimerix during the 4th quarter worth $130,000. Institutional investors and hedge funds own 45.42% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.